Jubilant Pharmova
Revenue rose 21% YoY to ₹2,370 Cr, but PAT was only ₹31 Cr as margins fell on Montreal losses (>₹80 Cr in Q2). Management guides H2 mid-teen margins and deferred FY28 guidance.
ALFA Concalls
Every earnings call, live and summarised
Earnings calls
Every Jubilant Pharmova earnings call we streamed: the live audio and our summary of what management said.
Revenue rose 21% YoY to ₹2,370 Cr, but PAT was only ₹31 Cr as margins fell on Montreal losses (>₹80 Cr in Q2). Management guides H2 mid-teen margins and deferred FY28 guidance.
Revenue rose 21% YoY to ₹2,370 Cr, but PAT was only ₹31 Cr as margins fell on Montreal losses (>₹80 Cr in Q2). Management guides H2 mid-teen margins and deferred FY28 guidance.
H2 average EBITDA margin mid-teens; FY27 capex ₹1,800–1,900 Cr, FY28 ~₹1,000 Cr; net debt ~₹4,000 Cr end-FY27.
Jubilant Pharmova Q4FY26 revenue grew 19% YoY to ₹2,290 Cr. FY26 revenue reached ₹8,280 Cr (up 14%) driven by CDMO Sterile Injectables and Radiopharma growth.
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.